UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.
Glycoconj J
; 26(6): 663-73, 2009 Aug.
Article
en En
| MEDLINE
| ID: mdl-19005752
ABSTRACT
As compared to cutaneous leishmaniasis, vaccination against visceral leishmaniasis (VL) has received limited attention. In this study, we demonstrate for the first time that an UDP-Galactose N-acetylglucosamine beta 1-4 galactosyltransferase (GenBank Accession No. EF159943) expressing attenuated LD clonal population (A-LD) is able to confer protection against the experimental challenge with the virulent LD AG83 parasite. A-LD was also effective in established leishmania infection. The vaccinated animals showed both cell mediated (in vitro T-cell proliferation, and DTH response) and humoral responses (Th1 type). These results demonstrate the potential of the attenuated clones as an immunotherapeutic and immunoprophylactic agent against visceral leishmaniasis.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Leishmania donovani
/
Vacunas Antiprotozoos
/
Galactosiltransferasas
/
Leishmaniasis Visceral
/
Antígenos de Protozoos
Límite:
Animals
Idioma:
En
Revista:
Glycoconj J
Asunto de la revista:
BIOQUIMICA
/
METABOLISMO
Año:
2009
Tipo del documento:
Article
País de afiliación:
India